Discontinuation report ROPIVACAINE HYDROCHLORIDE INJECTION USP
Report ID | 170502 |
Drug Identification Number | 02347822 |
Brand name | ROPIVACAINE HYDROCHLORIDE INJECTION USP |
Common or Proper name | ROPIVACAINE HYDROCHLORIDE INJECTION USP |
Company Name | PFIZER CANADA ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | ROPIVACAINE HYDROCHLORIDE |
Strength(s) | 5MG |
Dosage form(s) | SOLUTION |
Route of administration | EPIDURAL BLOCK/INFILTRATION EPIDURAL BLOCK/INFILTRATION |
Packaging size | 10 x 30mL vial |
ATC code | N01BB |
ATC description | ANESTHETICS, LOCAL |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | |
Actual discontinuation date | 2022-10-01 |
Remaining supply date | 2022-10-01 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2022-10-02 | English | Compare |
v2 | 2022-09-30 | French | Compare |
v1 | 2022-09-30 | English | Compare |
Showing 1 to 3 of 3